Xbrane Bioscience
Trending Articles
Related Content
Research & Development
Xbrane and STADA enter into a co-development agreement for Xlucane
Via a 50/50 split of expenses and profits, the companies will equally contribute to the development of Xlucane, a biosimilar to the VEGFa inhibitor ranibizumab (Lucentis) used in the treatment of several eye diseases